These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29244631)

  • 1. Initial Results of Peripheral-Blood Stem-Cell Mobilization, Collection, Cryopreservation, and Engraftment After Autologous Transplantation Confirm That the Capacity-Building Approach Offers Good Chances of Success in Critical Contexts: A Kurdish-Italian Cooperative Project at the Hiwa Cancer Hospital, Sulaymaniyah.
    Majolino I; Mohammed D; Hassan D; Ipsevich F; Abdullah C; Mohammed R; Palmas A; Possenti M; Noori D; Ali D; Karem H; Salih S; Vacca M; Del Fante C; Ostuni A; Frigato A; Massei MS; Manna A; Vasta S; Gabriel M; Verna M; Rovelli A; Conter V; Ali K; Othman D
    J Glob Oncol; 2018 Sep; 4(4):1-8. PubMed ID: 29244631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Start-Up of the first Hematopoietic Stem Cell Transplantation Center in the Iraqi Kurdistan: a Capacity-Building Cooperative Project by the Hiwa Cancer Hospital, Sulaymaniyah, and the Italian Agency for Development Cooperation: an Innovative Approach.
    Majolino I; Othman D; Rovelli A; Hassan D; Rasool L; Vacca M; Abdalrahman N; Abdullah C; Ahmed Z; Ali D; Ali K; Broggi C; Calabretta C; Canesi M; Ciabatti G; Del Fante C; De Sapio E; Dore G; Frigato A; Gabriel M; Ipsevich F; Kareem H; Karim D; Leone R; Mahmood T; Manna A; Massei MS; Mastria A; Mohammed D; Mohammed R; Najmaddin K; Noori D; Ostuni A; Palmas A; Possenti M; Qadir A; Real G; Shrif R; Valdatta C; Vasta S; Verna M; Vittori M; Yousif A; Zallio F; Calisti A; Quattrocchi S; Girmenia C
    Mediterr J Hematol Infect Dis; 2017; 9(1):e2017031. PubMed ID: 28512560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
    Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
    Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
    Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
    Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
    Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products.
    Sartor M; Antonenas V; Garvin F; Webb M; Bradstock KF
    Bone Marrow Transplant; 2005 Aug; 36(3):199-204. PubMed ID: 15937512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization.
    Kuan JW; Su AT; Wong SP; Sim XY; Toh SG; Ong TC; Rajasuriarr JS; Lim SH; Guan YK; Liew HK; Liew PK; Tan JT; Kori AN; Cheng YY; Tan SM; Chang KM
    Transfus Apher Sci; 2015 Oct; 53(2):196-204. PubMed ID: 25910537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.
    Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM
    Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
    Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
    Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.